|Bid||24.83 x 900|
|Ask||24.87 x 1400|
|Day's Range||24.63 - 25.06|
|52 Week Range||16.02 - 36.95|
|Beta (5Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for MYGN
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Myriad (MYGN) delivered earnings and revenue surprises of 100% and 6.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.